PIM1抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P07973(PIM1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The PIM1 antibody is a research tool targeting the Proviral Integration site for Moloney murine leukemia virus 1 (PIM1) kinase, a serine/threonine kinase involved in cell survival, proliferation, and apoptosis regulation. PIM1. part of the PIM kinase family (PIM1. PIM2. PIM3), is overexpressed in various cancers, including hematopoietic malignancies (e.g., leukemia, lymphoma) and solid tumors. It acts as an oncogene by phosphorylating substrates like c-MYC, BAD, and p21. promoting cell cycle progression and inhibiting apoptosis. Its expression is often linked to poor prognosis and therapy resistance.

PIM1 antibodies are widely used in biomedical research to detect PIM1 protein levels, localization, and activity in cells or tissues via techniques like Western blot, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies aid in studying PIM1's role in tumorigenesis, metastasis, and interactions with signaling pathways (e.g., JAK/STAT, PI3K/AKT). They also support drug development efforts, as PIM1 inhibitors are explored for cancer therapy. Structurally, PIM1 lacks a regulatory domain, making it constitutively active and dependent on expression levels for activity modulation.

Recent studies highlight PIM1's potential as a therapeutic target, though clinical success remains limited. Challenges include off-target effects of inhibitors and compensatory mechanisms by other kinases. PIM1 antibodies remain critical for validating target engagement in preclinical models and optimizing inhibitor specificity. Ongoing research focuses on combination therapies and biomarker identification to enhance PIM1-targeted treatment efficacy.